Gertraud Hanft

1.7k total citations
27 papers, 1.4k citations indexed

About

Gertraud Hanft is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Gertraud Hanft has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Cellular and Molecular Neuroscience and 7 papers in Oncology. Recurrent topics in Gertraud Hanft's work include Neuroscience and Neuropharmacology Research (11 papers), Receptor Mechanisms and Signaling (10 papers) and Microtubule and mitosis dynamics (4 papers). Gertraud Hanft is often cited by papers focused on Neuroscience and Neuropharmacology Research (11 papers), Receptor Mechanisms and Signaling (10 papers) and Microtubule and mitosis dynamics (4 papers). Gertraud Hanft collaborates with scholars based in Germany, United States and Netherlands. Gertraud Hanft's co-authors include Gerhard Groß, Norbert Kolassa, Karl Hoermann, Silke Gronau, Alexander Sauter, Herbert Riechelmann, MartinC. Michel, Gerd Munzert, Holger Fritsch and H. Maximilian Mehdorn and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Pharmacology and European Journal of Pharmacology.

In The Last Decade

Gertraud Hanft

27 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gertraud Hanft Germany 18 858 398 281 226 201 27 1.4k
Sylvie Cazaubon France 22 1.2k 1.4× 261 0.7× 283 1.0× 303 1.3× 299 1.5× 35 2.3k
Hakjoo Lee United States 28 1.3k 1.6× 520 1.3× 174 0.6× 194 0.9× 246 1.2× 38 2.1k
Nathalie Blin France 17 947 1.1× 467 1.2× 270 1.0× 95 0.4× 498 2.5× 29 1.6k
Kazuo Fushimi Japan 20 1.3k 1.5× 172 0.4× 113 0.4× 120 0.5× 293 1.5× 35 2.0k
Timothy Coskran United States 10 1.3k 1.5× 231 0.6× 303 1.1× 133 0.6× 322 1.6× 21 1.9k
Gillian M. Borthwick United Kingdom 19 1.1k 1.2× 160 0.4× 159 0.6× 64 0.3× 237 1.2× 28 1.8k
Cecylia Zaloga United States 9 874 1.0× 472 1.2× 130 0.5× 97 0.4× 351 1.7× 9 1.9k
Sucheta M. Vaingankar United States 19 798 0.9× 319 0.8× 131 0.5× 295 1.3× 172 0.9× 41 1.6k
Chen-Hsiung Yeh United States 15 941 1.1× 378 0.9× 73 0.3× 82 0.4× 243 1.2× 35 1.5k
Zhongji Liao United States 14 656 0.8× 157 0.4× 101 0.4× 156 0.7× 232 1.2× 21 1.6k

Countries citing papers authored by Gertraud Hanft

Since Specialization
Citations

This map shows the geographic impact of Gertraud Hanft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gertraud Hanft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gertraud Hanft more than expected).

Fields of papers citing papers by Gertraud Hanft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gertraud Hanft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gertraud Hanft. The network helps show where Gertraud Hanft may publish in the future.

Co-authorship network of co-authors of Gertraud Hanft

This figure shows the co-authorship network connecting the top 25 collaborators of Gertraud Hanft. A scholar is included among the top collaborators of Gertraud Hanft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gertraud Hanft. Gertraud Hanft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Riechelmann, Herbert, et al.. (2008). Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncology. 44(9). 823–829. 146 indexed citations
4.
Eichbaum, Michael, Florian Schuetz, Peter Schmidt, et al.. (2007). Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anti-Cancer Drugs. 18(4). 477–485. 78 indexed citations
5.
Colnot, David R., Jan C. Roos, Remco de Bree, et al.. (2003). Safety, biodistribution, pharmacokinetics, and immunogenicity of 99m Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunology Immunotherapy. 52(9). 576–582. 52 indexed citations
6.
Hanft, Gertraud, Dominique Turck, Stefan Scheuerer, & Ralf Sigmund. (2001). Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations. Inflammation Research. 50(S1). 35–37. 34 indexed citations
7.
Lemmel, E.‐M., W. Bolten, Rubén Burgos‐Vargas, et al.. (1997). Efficacy and safety of meloxicam in patients with rheumatoid arthritis.. PubMed. 24(2). 282–90. 35 indexed citations
8.
Hanft, Gertraud, et al.. (1994). Radioligand binding studies of α1‐adrenoceptor subtypes in rat heart. British Journal of Pharmacology. 111(2). 533–538. 53 indexed citations
9.
Hanft, Gertraud, et al.. (1994). Functional studies on α1‐adrenoceptor subtypes mediating inotropic effects in rat right ventricle. British Journal of Pharmacology. 111(2). 539–546. 37 indexed citations
10.
Mey, Christian de, et al.. (1991). Noninvasive assessment of the inodilator action of amrinone in healthy man. European Journal of Clinical Pharmacology. 40(4). 373–378. 4 indexed citations
11.
Groß, Gerhard, et al.. (1990). Urapidil Analogues Are Potent Ligands of the 5-HT1A Receptor. Journal of Cardiovascular Pharmacology. 15. S8–S16. 4 indexed citations
12.
Michel, MartinC., Gertraud Hanft, & Gerhard Groß. (1990). ?1B- but not ?1A-adrenoceptors mediate inositol phosphate generation. Naunyn-Schmiedeberg s Archives of Pharmacology. 341(4). 385–7. 50 indexed citations
13.
Groß, Gerhard, et al.. (1990). Urapidil Analogues Are Potent Ligands of the 5-HT1A Receptor. Journal of Cardiovascular Pharmacology. 15. S8–S16. 6 indexed citations
14.
15.
Hanft, Gertraud, et al.. (1990). Effect of hypo‐ and hyperthyroidism on binding of [3H]‐nitrendipine to myocardial and brain membranes.. British Journal of Clinical Pharmacology. 30(S1). 128S–130S. 4 indexed citations
16.
Groß, Gerhard, Gertraud Hanft, & H. Maximilian Mehdorn. (1989). Demonstration of α1A-and α1B-adrenoceptor binding sites in human brain tissue. European Journal of Pharmacology. 169(2-3). 325–328. 35 indexed citations
17.
Hanft, Gertraud & Gerhard Groß. (1989). Subclassification of α1‐adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. British Journal of Pharmacology. 97(3). 691–700. 195 indexed citations
18.
Groß, Gerhard, et al.. (1988). 5-Methyl-urapidil discriminates between subtypes of the α1-adrenoceptor. European Journal of Pharmacology. 151(2). 333–335. 191 indexed citations
19.
Groß, Gerhard, Christoph Dodt, & Gertraud Hanft. (1988). Effect of chronic lithium administration on adrenoceptor binding and adrenoceptor regulation in rat cerebral cortex. Naunyn-Schmiedeberg s Archives of Pharmacology. 337(3). 267–72. 21 indexed citations
20.
Hanft, Gertraud, et al.. (1987). Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for ?1-adrenoceptor binding sites. Naunyn-Schmiedeberg s Archives of Pharmacology. 336(6). 597–601. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvie Cazaubon Breakdown of academic impact, for papers by Hakjoo Lee Breakdown of academic impact, for papers by Nathalie Blin Breakdown of academic impact, for papers by Kazuo Fushimi Breakdown of academic impact, for papers by Timothy Coskran Breakdown of academic impact, for papers by Gillian M. Borthwick Breakdown of academic impact, for papers by Cecylia Zaloga Breakdown of academic impact, for papers by Sucheta M. Vaingankar Breakdown of academic impact, for papers by Chen-Hsiung Yeh Breakdown of academic impact, for papers by Zhongji Liao
Rankless by CCL
2026